A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures

Neurology

Volumn 48, Issue 4, 1997, Pages 1032-1037

  Gustavson, L E ^a   Boellner, S W ^b   Granneman, G R ^a   Qian, J X ^a   Guenther, H J ^a   El Shourbagy, T ^a   Sommerville, K W ^a  

^a ABBOTT LABORATORIES   (United States)

^b Neurology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; TIAGABINE; VALPROIC ACID;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030960662     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.4.1032     Document Type: Article

References (21)

1. Meldrum B. Pharmacology of GABA. Clin Neuropharmacol 1982;5:293-316.
2. Bartholini G. GABA receptor agonists: pharmacological spectrum and therapeutic actions. Med Res Rev 1985;5:55-75.
3. Croucher MJ, Meldrum BS, Krogsgaard-Larsen P. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. Eur J Pharmacol 1983;89:217-228.
4. Giardina WJ. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy 1994;7:161-166.
5. Nielsen EB, Suzdak PD, Anderson KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:257-266.
6. Rowan AJ, Uthman B, Ahmann P, et al. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures (abstract). Epilepsia 1994;35(suppl 8):54.
7. Crawford PM, Engelsman M, Brown SW, et al. Tiagabine: phase II study of efficacy and safety in adjunctive treatment of partial seizures [abstract]. Epilepsia 1993;34(suppl 2):182.
8. Sachdeo R, Leroy R, Krauss G, et al. Safety and efficacy of BID and QID dosing with tiagabine HCl versus placebo as adjunctive treatment for partial seizures [abstract]. Neurology 1995;45(suppl 4):A202.
9. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
10. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-611.
11. Mengel H, Gustavson LE, Soerensen HJ, McKelvy JF, Pierce MW, Houston A. Effect of food on the bioavailability of tiagabine HCl [abstract]. Epilepsia 1991;32(suppl 3):6.
12. Richens A, Gustavson LE, McKelvy JF, Mengel H, Deaton R, Pierce MW. Pharmacokinetics and safety of single-dose tiagabine HCl in epileptic patients chronically treated with four other antiepileptic drug regimens. Presented at the annual meeting of the American Epilepsy Society; December 9, 1991; Philadelphia.
13. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995;22:221-226.
14. Gustavson LE, Guenther HJ, Boellner SW, Granneman GR, Sommerville KW. A single dose study to define the pharmacokinetics of tiagabine in pediatric patients [abstract]. Neurology 1996;46(suppl 2):A176.
15. Gustavson LE, Chu S-y. High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr B Biomed Appl 1992;574:313-318.
16. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1975:293-296.
17. Du Bois D, Du Bois EF. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
18. Snel S, Mukherjee S, Richens A, Mengel HB. Pharmacokinetics of tiagabine in the elderly. Presented at the 20th International Epilepsy Congress; July 8, 1993; Oslo.
19. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995;23:1110-1116.
20. 14C-tiagabine in humans [abstract]. Epilepsia 1992;33(suppl 3):83.
21. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996;30:329-332.